Spitfire Capital Increased Its Libbey (LBY) Stake by $488,529; Alexion Pharmaceuticals (ALXN) Shareholder Third Point Trimmed Stake

January 13, 2018 - By Richard Conner

Julian Allen increased its stake in Libbey Inc (LBY) by 5.98% based on its latest 2017Q3 regulatory filing with the SEC. Spitfire Capital Llc bought 54,281 shares as the company’s stock declined 53.74% while stock markets rallied. The hedge fund run by Julian Allen held 961,437 shares of the capital goods company at the end of 2017Q3, valued at $8.90M, up from 907,156 at the end of the previous reported quarter. Spitfire Capital Llc who had been investing in Libbey Inc for a number of months, seems to be bullish on the $169.74M market cap company. The stock decreased 1.15% or $0.09 during the last trading session, reaching $7.71. About 156,597 shares traded. Libbey Inc. (NYSEMKT:LBY) has declined 48.72% since January 13, 2017 and is downtrending. It has underperformed by 65.42% the S&P500.

Dan Loeb decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 20% based on its latest 2017Q3 regulatory filing with the SEC. Third Point Llc sold 250,000 shares as the company’s stock declined 11.63% while stock markets rallied. The hedge fund run by Dan Loeb held 1.00 million shares of the health care company at the end of 2017Q3, valued at $140.29 million, down from 1.25M at the end of the previous reported quarter. Third Point Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $27.42 billion market cap company. The stock increased 0.19% or $0.23 during the last trading session, reaching $122.71. About 1.23 million shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since January 13, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Investors sentiment decreased to 0.97 in 2017 Q3. Its down 0.36, from 1.33 in 2017Q2. It turned negative, as 10 investors sold LBY shares while 29 reduced holdings. 7 funds opened positions while 31 raised stakes. 17.24 million shares or 0.23% more from 17.20 million shares in 2017Q2 were reported. Prelude Cap Management Ltd Liability Com reported 1,500 shares. Royal Natl Bank Of Canada holds 0.01% of its portfolio in Libbey Inc. (NYSEAMERICAN:LBY) for 1.24 million shares. Moreover, Lsv Asset has 0% invested in Libbey Inc. (NYSEAMERICAN:LBY) for 162,900 shares. State Board Of Administration Of Florida Retirement Sys accumulated 13,946 shares. Boston Prns reported 0.01% of its portfolio in Libbey Inc. (NYSEAMERICAN:LBY). Pub Employees Retirement Association Of Colorado holds 0% in Libbey Inc. (NYSEAMERICAN:LBY) or 6,520 shares. Bnp Paribas Arbitrage has 2,955 shares. New York-based Morgan Stanley has invested 0% in Libbey Inc. (NYSEAMERICAN:LBY). California State Teachers Retirement Systems holds 0% of its portfolio in Libbey Inc. (NYSEAMERICAN:LBY) for 36,032 shares. Intl Group Inc Inc owns 14,700 shares for 0% of their portfolio. Prudential Financial reported 49,132 shares. Albion Gru Ut has invested 0.05% in Libbey Inc. (NYSEAMERICAN:LBY). Northern Trust owns 299,257 shares. Rhumbline Advisers, a Massachusetts-based fund reported 26,448 shares. Brigade Mngmt Lp holds 0.74% or 990,000 shares in its portfolio.

Among 28 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 23 have Buy rating, 0 Sell and 5 Hold. Therefore 82% are positive. Alexion Pharmaceuticals Inc. had 89 analyst reports since July 27, 2015 according to SRatingsIntel. On Monday, September 26 the stock rating was maintained by Leerink Swann with “Outperform”. JP Morgan initiated Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Monday, July 27 with “Overweight” rating. Morgan Stanley upgraded the shares of ALXN in report on Friday, October 2 to “Overweight” rating. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Morgan Stanley on Friday, July 28. The firm has “Neutral” rating by Wedbush given on Friday, September 23. The rating was maintained by Leerink Swann on Wednesday, September 13 with “Buy”. The firm earned “Underperform” rating on Thursday, September 15 by FBR Capital. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Friday, July 31 by Brean Capital. The stock has “Buy” rating by Goldman Sachs on Friday, October 28. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, October 27.

Third Point Llc, which manages about $17.97 billion and $11.90B US Long portfolio, upped its stake in Vulcan Matls Co (NYSE:VMC) by 750,000 shares to 2.35 million shares, valued at $281.06M in 2017Q3, according to the filing. It also increased its holding in Alibaba Group Hldg Ltd (NYSE:BABA) by 2.10 million shares in the quarter, for a total of 6.60M shares, and has risen its stake in F M C Corp (NYSE:FMC).

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 15. They expect $1.08 earnings per share, down 1.82% or $0.02 from last year’s $1.1 per share. ALXN’s profit will be $241.29 million for 28.41 P/E if the $1.08 EPS becomes a reality. After $1.28 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -15.63% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>